These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Selection and adaptation during metastatic cancer progression. Klein CA Nature; 2013 Sep; 501(7467):365-72. PubMed ID: 24048069 [TBL] [Abstract][Full Text] [Related]
5. The challenge of intratumour heterogeneity in precision medicine. Seoane J; De Mattos-Arruda L J Intern Med; 2014 Jul; 276(1):41-51. PubMed ID: 24661605 [TBL] [Abstract][Full Text] [Related]
6. Tumour heterogeneity and resistance to cancer therapies. Dagogo-Jack I; Shaw AT Nat Rev Clin Oncol; 2018 Feb; 15(2):81-94. PubMed ID: 29115304 [TBL] [Abstract][Full Text] [Related]
7. The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome. Caswell DR; Swanton C BMC Med; 2017 Jul; 15(1):133. PubMed ID: 28716075 [TBL] [Abstract][Full Text] [Related]
8. Clonal evolution and heterogeneity in metastatic head and neck cancer-An analysis of the Austrian Study Group of Medical Tumour Therapy study group. Melchardt T; Magnes T; Hufnagl C; Thorner AR; Ducar M; Neureiter D; Tränkenschuh W; Klieser E; Gaggl A; Rösch S; Rasp G; Hartmann TN; Pleyer L; Rinnerthaler G; Weiss L; Greil R; Egle A Eur J Cancer; 2018 Apr; 93():69-78. PubMed ID: 29477794 [TBL] [Abstract][Full Text] [Related]
10. Constraints in cancer evolution. Venkatesan S; Birkbak NJ; Swanton C Biochem Soc Trans; 2017 Feb; 45(1):1-13. PubMed ID: 28202655 [TBL] [Abstract][Full Text] [Related]
11. Investigating intratumour heterogeneity by single-cell sequencing. Ren SC; Qu M; Sun YH Asian J Androl; 2013 Nov; 15(6):729-34. PubMed ID: 24141534 [TBL] [Abstract][Full Text] [Related]
12. Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma. Fattore L; Ruggiero CF; Liguoro D; Mancini R; Ciliberto G Cell Death Dis; 2019 Oct; 10(11):827. PubMed ID: 31672982 [TBL] [Abstract][Full Text] [Related]
13. Capturing Tumor Heterogeneity and Clonal Evolution by Circulating Tumor DNA Profiling. Scherer F Recent Results Cancer Res; 2020; 215():213-230. PubMed ID: 31605231 [TBL] [Abstract][Full Text] [Related]
14. Clinical trial designs for evaluating and exploiting cancer evolution. Ingles Garces AH; Porta N; Graham TA; Banerji U Cancer Treat Rev; 2023 Jul; 118():102583. PubMed ID: 37331179 [TBL] [Abstract][Full Text] [Related]
15. Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution. Kim JY; Gatenby RA Methods Mol Biol; 2017; 1513():61-81. PubMed ID: 27807831 [TBL] [Abstract][Full Text] [Related]
16. Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale. Barber LJ; Davies MN; Gerlinger M Curr Opin Genet Dev; 2015 Feb; 30():1-6. PubMed ID: 25555261 [TBL] [Abstract][Full Text] [Related]
17. Tumour heterogeneity and the evolution of polyclonal drug resistance. Burrell RA; Swanton C Mol Oncol; 2014 Sep; 8(6):1095-111. PubMed ID: 25087573 [TBL] [Abstract][Full Text] [Related]
18. Advances for studying clonal evolution in cancer. Ding L; Raphael BJ; Chen F; Wendl MC Cancer Lett; 2013 Nov; 340(2):212-9. PubMed ID: 23353056 [TBL] [Abstract][Full Text] [Related]
19. Multiregion Sequence Analysis to Predict Intratumor Heterogeneity and Clonal Evolution. Ahn S; Huang H Methods Mol Biol; 2021; 2243():283-296. PubMed ID: 33606263 [TBL] [Abstract][Full Text] [Related]
20. Principles of Reconstructing the Subclonal Architecture of Cancers. Dentro SC; Wedge DC; Van Loo P Cold Spring Harb Perspect Med; 2017 Aug; 7(8):. PubMed ID: 28270531 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]